{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:52:36Z","timestamp":1760953956067},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Transcripts of human endogenous retrovirus K are expressed in most breast cancers (BCs). Yellow fever vaccine 17D (YFV) expresses a protein with a closely homologous epitope. Cross-reactive immunity could hypothetically inhibit BC growth at least in women aged around 50 years at diagnosis, in whom the prognosis of BC was found to be better than that in women younger or older. A cohort of 12\u2009804 women who received YFV in the Veneto Region, Italy, was divided into two subcohorts according to age at vaccination and followed up through the Veneto Tumor Registry. The time since vaccination until cancer incidence was categorized (\u22641.9; 2\u20133.9; 4\u20135.9; 6\u20137.9; 8\u201310.9; \u226511 years) and, using the lowest class as a reference, the incidence rate ratio for BC with a 95% confidence interval and <jats:italic toggle=\"yes\">P<\/jats:italic>-value was estimated by Poisson regression in each time since vaccination class, adjusting for age and calendar period. In 3140 women vaccinated at 40\u201354 years of age, YFV administration resulted in a protective effect of long duration slowly fading over time with a U-shaped pattern of response. Overall, BC risk was reduced by about 50% (incidence rate ratio=0.46; 95% confidence interval=0.26\u20130.83; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.009) 2 years after vaccination. Cross-reactive antigens could not be the mechanism because no protection was observed in women vaccinated before 40 or after 54 years of age. BC cells in a microscopic stage of disease can be destroyed or severely damaged by YFV if BC is not very aggressive. To prove that treatment is truly effective, a placebo-controlled double-blind trial should be conducted.<\/jats:p>","DOI":"10.1097\/cej.0000000000000333","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T21:06:13Z","timestamp":1479503173000},"page":"303-309","source":"Crossref","is-referenced-by-count":5,"title":["Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study"],"prefix":"10.1097","volume":"27","author":[{"given":"Giuseppe","family":"Mastrangelo","sequence":"first","affiliation":[{"name":"Cardiac, Thoracic and Vascular Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Pavanello","sequence":"additional","affiliation":[{"name":"Cardiac, Thoracic and Vascular Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Fadda","sequence":"additional","affiliation":[{"name":"Cardiac, Thoracic and Vascular Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Buja","sequence":"additional","affiliation":[{"name":"Molecular Medicine, University of Padova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Fedeli","sequence":"additional","affiliation":[{"name":"Regional Epidemiology Service, Veneto Region, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198608283150906","article-title":"The relation between survival and age at diagnosis in breast cancer","volume":"315","author":"Adami","year":"1986","journal-title":"N Engl J Med"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1055-9965.EPI-06-0191","article-title":"Comparison of age distribution patterns for different histopathologic types of breast carcinoma","volume":"15","author":"Anderson","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","article-title":"Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy","volume":"29","author":"Arvold","year":"2011","journal-title":"J Clin Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-13-4","article-title":"Human endogenous retroviruses and cancer prevention: evidence and prospects","volume":"13","author":"Cegolon","year":"2013","journal-title":"BMC Cancer"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2010.32.6462","article-title":"Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics","volume":"29","author":"Colzani","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0140-6736(93)92407-K","article-title":"Age as prognostic factor in premenopausal breast carcinoma","volume":"341","author":"De la Rochefordiere","year":"1993","journal-title":"Lancet"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.29003","article-title":"Human endogenous retrovirus K and cancer: innocent bystander or tumorigenic accomplice?","volume":"137","author":"Downey","year":"2015","journal-title":"Int J Cancer"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/cgt.2011.90","article-title":"Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells","volume":"19","author":"Gao","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J Clin Oncol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1016\/j.vaccine.2012.04.074","article-title":"The yellow fever 17D vaccine and risk of malignant melanoma in the United States military","volume":"30","author":"Hodges-Vazquez","year":"2012","journal-title":"Vaccine"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0959-8049(97)89017-X","article-title":"Effect of age on the survival of breast cancer patients","volume":"33","author":"Holli","year":"1997","journal-title":"Eur J Cancer"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T","article-title":"Age as a prognostic factor in breast cancer","volume":"57","author":"H\u00f8st","year":"1986","journal-title":"Cancer"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1445-2197.2005.03515.x","article-title":"Is age at diagnosis an independent prognostic factor for survival following breast cancer?","volume":"75","author":"Jayasinghe","year":"2005","journal-title":"ANZ J Surg"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00008390-199910000-00011","article-title":"Infections and melanoma risk: results of a multicentre EORTC case\u2013control study. European Organization for Research and Treatment of Cancer","volume":"9","author":"K\u00f6lmel","year":"1999","journal-title":"Melanoma Res"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2004.09.023","article-title":"Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients","volume":"41","author":"K\u00f6lmel","year":"2005","journal-title":"Eur J Cancer"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.3747\/co.21.1604","article-title":"Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis","volume":"21","author":"Kong","year":"2014","journal-title":"Curr Oncol"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-011-1347-z","article-title":"Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms","volume":"128","author":"Kravchenko","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00432-010-0949-x","article-title":"Melanoma, Darwinian medicine and the inner world","volume":"136","author":"Krone","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0959-8049(03)00625-7","article-title":"Impact of vaccinations and infectious diseases on the risk of melanoma \u2013 evaluation of an EORTC case\u2013control study","volume":"39","author":"Krone","year":"2003","journal-title":"Eur J Cancer"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2004.08.010","article-title":"Protection against melanoma by vaccination with Bacille Calmette\u2013Guerin (BCG) and\/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control","volume":"41","author":"Krone","year":"2005","journal-title":"Eur J Cancer"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/1471-2407-14-595","article-title":"The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies","volume":"14","author":"Krone","year":"2014","journal-title":"BMC Cancer"},{"key":"R27-20230902","first-page":"1259","article-title":"Relationship of ethnicity and other prognostic factors to breast cancer survival patterns in Hawaii","volume":"73","author":"LeMarchand","year":"1984","journal-title":"J Natl Cancer Inst"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1586\/14760584.2013.845530","article-title":"Preclinical vaccines against mammary carcinoma","volume":"12","author":"Lollini","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.vaccine.2008.10.076","article-title":"Does yellow fever 17D vaccine protect against melanoma?","volume":"27","author":"Mastrangelo","year":"2009","journal-title":"Vaccine"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-20230902","first-page":"301","article-title":"Global Advisory Committee on Vaccine Safety 12\u201313 June 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1158\/1078-0432.CCR-12-3661","article-title":"Infection and cancer: revaluation of the hygiene hypothesis","volume":"19","author":"Oikonomopoulou","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/157340708786847870","article-title":"Reverse pharmacology and systems approaches for drug discovery and development","volume":"4","author":"Patwardhan","year":"2008","journal-title":"Curr Bioact Compd"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1523-1747.2002.00643.x","article-title":"Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study","volume":"119","author":"Pfahlberg","year":"2002","journal-title":"J Invest Dermatol"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.immuni.2010.10.006","article-title":"Systems vaccinology","volume":"33","author":"Pulendran","year":"2010","journal-title":"Immunity"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1126\/science.1246829","article-title":"Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation","volume":"343","author":"Ravindran","year":"2014","journal-title":"Science"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<679::AID-IJC3>3.0.CO;2-S","article-title":"Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group","volume":"77","author":"Sant","year":"1998","journal-title":"Int J Cancer"},{"key":"R38-20230902","first-page":"5510","article-title":"A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes","volume":"62","author":"Schiavetti","year":"2002","journal-title":"Cancer Res"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3201\/eid1710.101789","article-title":"Yellow fever virus vaccine-associated deaths in young women","volume":"17","author":"Seligman","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"R41-20230902","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10549-013-2500-7","article-title":"Trends in breast cancer incidence and mortality in the United States: implications for prevention","volume":"138","author":"Toriola","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"R42-20230902","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/tbj.12127","article-title":"Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy","volume":"19","author":"Vicini","year":"2013","journal-title":"Breast J"},{"issue":"Suppl 1","key":"R43-20230902","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1475-2875-10-S1-S8","article-title":"A \u2018reverse pharmacology\u2019 approach for developing an anti-malarial phytomedicine","volume":"10","author":"Willcox","year":"2011","journal-title":"Malar J"},{"key":"R44-20230902","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/1947601911431841","article-title":"Expression of human endogenous retrovirus type K envelope protein is a novel candidate prognostic marker for human breast cancer","volume":"2","author":"Zhao","year":"2011","journal-title":"Genes Cancer"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008469-201807000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:01:00Z","timestamp":1693616460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008469-201807000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000333","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}